Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Original Article

Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease

Saba Sayari, Hassan Neishaboori, Maryam Jameshorani

Clin Mol Hepatol. 2018;24(3):331-338. Published online June 12, 2018

DOI: https://doi.org/10.3350/cmh.2018.0006

View: 8282 Download: 180 Web of Science: 29 Crossref: 32

Editorial

Combination of synbiotic and sitagliptin in nonalcoholic fatty liver disease: Is it better than sitagliptin alone?

Yong Kyun Cho

Clin Mol Hepatol. 2018;24(3):299-301. Published online September 7, 2018

DOI: https://doi.org/10.3350/cmh.2018.1006

View: 5677 Download: 105

Review

Imaging evaluation of non-alcoholic fatty liver disease: focused on quantification

Dong Ho Lee

Clin Mol Hepatol. 2017;23(4):290-301. Published online October 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0042

View: 20884 Download: 477 Web of Science: 95 Crossref: 92

NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs

Stephen Caldwell

Clin Mol Hepatol. 2017;23(2):103-108. Published online May 10, 2017

DOI: https://doi.org/10.3350/cmh.2017.0103

View: 12013 Download: 473 Web of Science: 30 Crossref: 31

Original Article

Regional prevalence of non-alcoholic fatty liver disease in Seoul and Gyeonggi-do, Korea

Eun Haeng Jeong, Dae Won Jun, Yong Kyun Cho, Young Gil Choe, Seungho Ryu, Seung Min Lee, Eun Chul Jang

Clin Mol Hepatol. 2013;19(3):266-272. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.266

View: 9189 Download: 98 Crossref: 67

Editorial

Chasing after novel non-invasive markers to identify advanced fibrosis in NAFLD

Wonseok Kang, Seung Up Kim

Clin Mol Hepatol. 2013;19(3):255-257. Published online September 30, 2013

DOI: https://doi.org/10.3350/cmh.2013.19.3.255

View: 5687 Download: 48 Crossref: 2

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Received March 1, 2024 Accepted March 5, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157 [Epub ahead of print]

PDF

View: 563 Download: 69

Original Article

Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against non-alcoholic fatty liver disease

Yiyuan Zheng, Lina Zhao, Zhekun Xiong, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Yugang Fu, Simin Gu, Chong Chen, Jiacheng Li, Yingying Zhu, Jing Liu, Fengbin Liu, Yong Li

Received January 18, 2024 Accepted April 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0047 [Accepted]

PDF

View: 378 Download: 48

1 | 2 | 3 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

8.9
First decision

09 Days

Publication after acceptance

04 Days

*Last 12 months

MOST VIEWED MOST CITED

MOST VIEWED (Last 6 months)

Viewed By 5544	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 4741	MAFLD: How is it different from NAFLD?
Viewed By 4469	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3664	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3638	Global incidence and prevalence of nonalcoholic fatty liver disease

MOST CITED (2022-2024)

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 78	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 68	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 57	MAFLD: How is it different from NAFLD?

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

Copyright © The Korean Association for the Study of the Liver.

COUNTER

TODAY : 1369

TOTAL : 1807829